HOME >> BIOLOGY >> NEWS
Rare Tibetan antelope listed as endangered

The Bronx Zoo-based Wildlife Conservation Society (WCS) today applauded a decision today by the U.S. Fish and Wildlife Service to list the Tibetan antelope, also known as "chiru," as an endangered species. Through a series of expeditions to China's windswept Chang Tang Reserve over the past two decades, WCS had played a key role in sounding the alarm about the dramatic decline of this elegant animal due to poaching.

The antelope's wool, considered the finest in the world, is used for "shahtoosh" shawls (shahtoosh translates to "king of wool"), which are sold in the black market for up to $15,000 each. In the 1980s and 1990s, smuggled shawls made their way to European and U.S. markets, and became elite though highly illegal fashion statements. With such a high price on its head, tens of thousands of antelope have been slaughtered in recent years.

The U.S. Fish and Wildlife Service is listing the Tibetan antelope under the Endangered Species Act, reinforcing protection for an animal already safeguarded under the Convention on International Trade in Endangered Species (CITES), which means that the species, including its parts and products, is prohibited from international trade for commercial purposes. The listing, published in today's Federal Register, takes effect April 28, 2006.

"With today's listing, the United States has made a real commitment to helping ensure the future of this beautiful species," said Dr. George Schaller of the Wildlife Conservation Society. "We commend the U.S. Fish and Wildlife Service for its decision to provide even more protection to the Tibetan antelope through the Endangered Species Act, one of this country's most important environmental laws."

Working with Chinese biologists, Dr. Schaller was the first western scientists to document the biology of the chiru, which lives in the isolated Tibetan plateau in China.

An upcoming National Geographic film will chronicle the plight of the chir
'"/>


30-Mar-2006


Page: 1 2

Related biology news :

1. Tibetan antelope slowly recovering, WCS says
2. Asias odd-ball antelope gets collared
3. HIV protein enlisted to help kill cancer cells
4. Scientists find endangered grey-shanked doucs in Vietnam
5. Legal ruling may put endangered species in danger
6. Update on census of wrlds most endangered cat -- female Amur leopard found dead
7. Saving endangered whales at no cost
8. Climate change has surprising effect on endangered naked carp
9. A human taste for rarity spells disaster for endangered species
10. Cambodia moves to protect endangered bird
11. Race to halt global amphibian crisis boosted by rediscovery of endangered Colombian frogs

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Rare Tibetan antelope listed endangered

(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
(Date:4/16/2015)... 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced today the appointment of ... as Chief Operating Officer (COO). Cooper brings to ... developing clinical diagnostic and biotechnology platforms in the ... Cooper’s extensive career transcends the field of medical ...
(Date:4/16/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. ... the orphan disorder, neurotrophic keratopathy (NK), and a ... (DES) in the U.S.  Both trials will be ... Each of these eye disorders was being targeted ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
Cached News: